{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.2","upperLimit":"65.0","value":"51.7"},{"groupId":"OG001","lowerLimit":"75.4","upperLimit":"94.1","value":"86.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Non-Hodgkin Lymphoma (NHL): Diffuse Large B-cell Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: Follicular Lymphoma Grade 3B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.8","upperLimit":"66.0","value":"42.9"},{"groupId":"OG001","lowerLimit":"59.7","upperLimit":"94.8","value":"81.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NIH: High-Grade B-cell Lymphoma with DLBCL Histology"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"70.1","value":"33.3"},{"groupId":"OG001","lowerLimit":"63.1","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"NIH: Primary Mediastinal (thymic) Large B-cell Lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: T Cell/Histiocyte-Rich Large B-Cell Lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.3","upperLimit":"68.2","value":"54.0"},{"groupId":"OG001","lowerLimit":"74.7","upperLimit":"94.5","value":"86.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Diffuse Large B-cell Lymphoma (DLBCL): DLBCL NOS de novo"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"75.5","value":"37.5"},{"groupId":"OG001","lowerLimit":"42.1","upperLimit":"99.6","value":"85.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"DLBCL: DLBCL from Transformed Indolent NHL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.8","upperLimit":"66.2","value":"50.0"},{"groupId":"OG001","lowerLimit":"78.8","upperLimit":"97.5","value":"91.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"DLBCL: Germinal Center B-cell like (GCB)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.4","upperLimit":"64.3","value":"44.8"},{"groupId":"OG001","lowerLimit":"63.7","upperLimit":"97.0","value":"85.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"DLBCL: Activated B-cell-like, non-GCB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.1","upperLimit":"63.9","value":"40.0"},{"groupId":"OG001","lowerLimit":"59.7","upperLimit":"94.8","value":"81.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NHL: Double-hit lymphoma (DBL)/triple-hit lymphoma (THL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.3","upperLimit":"63.3","value":"51.4"},{"groupId":"OG001","lowerLimit":"78.7","upperLimit":"94.9","value":"88.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"NHL: Non-DHL/THL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants achieving a best overall response of partial response (PR) or complete response (CR). CR: Target nodes masses must regress to ≤ 1.5cm in LDi, no extralymphatic sites, no new lesions. PR: ≥ 50% decrease in sum of diameters of up to 6 target nodes and extranodal sites, no new lesions, spleen must have regressed \\> 50% in length. Complete metabolic response: Lymph nodes score 1, 2, 3 with/without residual mass on 5-point scale, no new lesions, no FDG-avid disease. Partial metabolic response: Lymph nodes score 4 or 5, reduced uptake from baseline, no new lesions, residual uptake higher than normal, reduced from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"NUMBER","populationDescription":"All randomized participants per clinical, histological and molecular subgroups that are pre-specified for ORR (subgroups are not mutually exclusive and participants are not exclusive to one subgroup)","reportingStatus":"POSTED","timeFrame":"From randomization to PR or CR (Up to 36 months)","title":"Overall Response Rate (ORR) by Subgroups","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}